Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246043 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL83981 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL254634 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL60113 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9093899 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31290858 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Ammonia Solution, Strong SCHEMBL25381565 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Water SCHEMBL9834733 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Water SCHEMBL9674541 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27412184 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | claimed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | claimed |
| EP-4317147-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2024-02-07 | — | — | EP | claimed |
| CN-117355515-A | Piperazine derivatives and their use | 广州白云山医药集团股份有限公司白云山制药总厂 | 2024-01-05 | — | — | CN | claimed |
| WO-2022228317-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | 广州白云山医药集团股份有限公司白云山制药总厂 | 2022-11-03 | — | — | WO | claimed |
| WO-2022203466-A1 | NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF | 주식회사 스탠다임 | 2022-09-29 | — | — | WO | claimed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | claimed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | claimed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | claimed |
| WO-2012175520-A1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | claimed |
| CN-101203516-A | Purine and imidazopyridine derivatives for immunosuppression | PHARMACOPEIA INC (US) | 2008-06-18 | — | — | CN | claimed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | claimed |
| US-6808762-B2 | Oxabicyclooctanes | MERCK PATENT GMBH (DE) | 2004-10-26 | — | — | US | claimed |
| US-20030215580-A1 | Oxabicyclooctanes | MERCK PATENT GMBH (DE) | 2003-11-20 | — | — | US | claimed |
| US-4263208-A | FROM DIENE, ALDEHYDE, GRIGNARD REAGENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-04-21 | — | — | US | claimed |
| US-4242269-A | DIELS-ALDER REACTION, GRIGNARD REAGENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-12-30 | — | — | US | claimed |
| US-4224176-A | Use of 2-oxabicyclooctane derivatives in augmenting or enhancing the aroma of detergents | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-09-23 | — | — | US | claimed |
| US-4208308-A | 2-Oxabicyclooctane derivatives in perfume compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-06-17 | — | — | US | claimed |
| US-4206092-A | PERFUMES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1980-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CHRM2 522/4885CHRM4 2012/4885CHRM5 1009/4885 |
| US-20030215580-A1 | Oxabicyclooctanes | CCNT1, OXA1L, CCNA1 | CHRM2 111/4885CHRM4 927/4885CHRM5 1262/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CHRM2 522/4885CHRM4 2012/4885CHRM5 1009/4885 |
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | CHRM2 2839/4885CHRM4 3868/4885CHRM5 2539/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CHRM2 752/4885CHRM4 2516/4885CHRM5 1259/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | CHRM2 1295/4885CHRM4 1943/4885CHRM5 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.